Zosano Pharma Announces FDA Acceptance of 505(b)(2) New Drug Application for Qtrypta(TM) for the Acute Treatment of Migraine

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11
Zosano Pharma Reports First Quarter 2022 Financial Results
Zosano Pharma Provides Corporate Update
Zosano Pharma Announces Reverse Stock Split Effective Today
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants
Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants
CORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.